EGFR Update: Improving Outcomes in EGFR-Mutated Non-Small-Cell Cancer

TOGA Podcast

English - March 29, 2022 17:10 - 26 minutes - 24 MB
Medicine Health & Fitness lung cancer oncology toga Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: The need for a National Clinical Quality Registry in Lung Cancer

Next Episode: Consider Every Trial as a TeleTrial

Welcome to the Thoracic Oncology Group of Australasia Podcast series. Today Rachel Roberts-Thomson, Medical Oncologist from Queen Elizabeth Hospital in Adelaide, discusses Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer . Rachel is joined byVenessa Chin from St. Vincent’s Hospital in Sydney & Angeline Low who has her own personal experience with EGFR lung cancer .

EGFR mutations are identified in approximately 15% of NSCLC patients. Efficacious, PBS-reimbursed first line treatments are available, but resistance to treatment and progression remains a concern. In this podcast, options for treatment post-progression are discussed, including accessible treatment and sequencing options and the role of patient preferences and clinical trials.

In collaboration/partnership/supported with/by Roche.

Disclaimer: The opinions, beliefs and viewpoints expressed by the various authors and participants contained in this message do not necessarily reflect the opinions, beliefs and viewpoints of TOGA or official policies of TOGA. Dosage & administration of any treatments mentioned during TOGA medical education may differ between Regions. Please refer to your local prescribing information for further details.

Note: SRS is Stereotactic radiosurgery